Monocef (Ceftriaxone + Sulbactam) Dosing for Adults
For adults, the standard dose of Monocef (ceftriaxone + sulbactam fixed-dose combination) is 1.5 g (1000 mg ceftriaxone + 500 mg sulbactam) administered intravenously every 12 hours, with a maximum daily dose not exceeding 3 g total per day. 1
Standard Adult Dosing Regimens
For Most Infections
- 1.5 g IV every 12 hours (1000 mg ceftriaxone + 500 mg sulbactam per dose) 2, 3
- Administer as IV infusion over 30 minutes 1
- Maximum total daily dose: 3 g 2
Severe or Complicated Infections
- 3 g IV every 12 hours may be considered for bacteria with MIC 8-32 μg/mL 2
- For MIC ≤8 μg/mL, 3 g total daily dose (1.5 g every 12 hours) is adequate 2
Important Dosing Considerations
Duration of Therapy
- Typical duration: 4-14 days depending on infection type and severity 1
- Continue therapy for at least 2 days after signs and symptoms resolve 1
- For Streptococcus pyogenes infections: minimum 10 days 1
Renal/Hepatic Impairment
- No dosage adjustment necessary for renal or hepatic impairment unless both are severely compromised 1
- Maximum 2 g/day in elderly patients with severe renal and hepatic impairment 1
Administration Guidelines
IV Preparation
- Reconstitute with appropriate IV diluent (sterile water, 0.9% sodium chloride, or 5% dextrose) 1
- Final concentration should be 10-40 mg/mL 1
- Avoid calcium-containing diluents (Ringer's solution, Hartmann's solution) due to precipitation risk 1
Infusion Protocol
- Administer over 30 minutes for adults 1
- Flush IV lines thoroughly between administrations if using with other medications 1
- Do not mix with vancomycin, aminoglycosides, amsacrine, or fluconazole 1
Clinical Evidence Supporting Dosing
The fixed-dose combination shows no pharmacokinetic interaction between ceftriaxone and sulbactam components 2. Population pharmacokinetic modeling demonstrates that weight is the primary covariate affecting drug exposure, but standard dosing remains appropriate across adult weight ranges 2.
In clinical trials for complicated urinary tract infections with multidrug-resistant pathogens (98% ceftriaxone non-susceptible, 83% ESBL-positive), the 1.5 g every 12 hours regimen achieved 95.9% symptomatic resolution and 94.6% microbiological eradication, demonstrating non-inferiority to meropenem 3.
Common Pitfalls to Avoid
- Never co-administer with calcium-containing IV solutions via Y-site, as ceftriaxone-calcium precipitation can occur 1
- Do not exceed 4 g total daily dose of the ceftriaxone component 1
- Avoid sequential administration with incompatible antibiotics without thorough line flushing 1
- Do not use in patients with known hypersensitivity to cephalosporins or beta-lactamase inhibitors 1